|
Patent landscape, scope, and claims: |
What is the scope of U.S. Patent 8,623,410?
U.S. Patent 8,623,410 was granted on December 31, 2013, to Bayer Aktiengesellschaft. It covers a method for diagnosing or predicting the risk of depression by measuring levels of specific lipid biomarkers in biological samples. The patent claims focus on lipid profiling as a diagnostic tool, particularly involving phosphatidylcholines and sphingomyelins, which are indicative of depression risk or presence.
The patent's claims are divided into two main categories:
Diagnostic method claims
- Claims utilize lipid levels as biomarkers for depression.
- The claims specify methods involving collecting biological samples (blood, plasma, serum) and analyzing lipid content.
- The analytical steps include mass spectrometry or comparable techniques for lipid quantification.
- Threshold levels of various lipids (e.g., specific phosphatidylcholine species such as PC(38:4), PC(40:6); sphingomyelins like SM(d18:1/16:0)) determine depression risk.
- The claims specify that the method can distinguish between depressive patients and control subjects or predict future depressive episodes.
Composition claims
- The patent contemplates compositions comprising lipid markers or calibrators for adjusting analytical measurements.
- These are used to standardize tests or validate diagnostic procedures.
The scope emphasizes lipid biomarker-based diagnostics for depression, rather than therapeutic methods or drug compositions.
How is the patent claim language structured?
Claims are technical and specific, focusing on the combination of biological sample analysis, lipid quantification, and threshold-based interpretation. For example:
-
Claim 1: A method comprising analyzing a biological sample to quantify at least one lipid biomarker selected from a list of phosphatidylcholines and sphingomyelins and comparing the levels to predetermined thresholds to diagnose or predict depression.
-
Claim 5: The method of claim 1, wherein the lipid biomarker comprises PC(38:4).
-
Claim 10: A method as in claim 1, further involving statistical analysis to enhance predictive accuracy.
Dependent claims specify particular lipid species, analytical techniques, and thresholds, with variations to cover different embodiments.
What does the patent landscape look like around U.S. Patent 8,623,410?
The landscape focuses on lipid-based diagnostics for depression and psychiatric conditions, featuring multiple patents from academic and industry entities.
Key patent families and stakeholders:
| Patent/Family |
Owner |
Focus |
Filing Date |
Key Claims |
Status |
| U.S. Patent 8,623,410 |
Bayer AG |
Lipid biomarkers for depression diagnosis |
April 16, 2012 |
Lipid profiling, threshold analysis |
Granted 2013 |
| EP Patent Application (EP 2,771,654) |
Bayer AG |
Similar lipid biomarkers |
Filed 2014 |
Diagnostic methods, lipid panels |
Pending |
| US Patent Application (2017/0074101) |
University of Helsinki |
Lipid biomarkers in psychiatric conditions |
Filed 2015 |
Lipid profiles for depression prediction |
Pending |
Competitors and collaborators:
- Several universities, including the University of Helsinki, have filed similar patent applications, indicating active research and potential for patent fencing.
- Companies like SomaLogic and Thermo Fisher pursue biomarker panels that include lipid species for neuropsychiatric diagnostics.
- No direct patent challenges or litigations are publicly documented against U.S. 8,623,410, suggesting a clear or uncontested IP position at the time of filing.
Trends and implications:
- Lipid biomarkers are increasingly emerging as diagnostic tools in depression and other neuropsychiatric disorders.
- The patent's broad claim scope on lipid profiling techniques indicates potential coverage of analytical methods, which can impact competitors’ R&D efforts.
- Patent expiration is expected around 2033, depending on terminal disclaimers and USPTO adjustments.
How broad are the claims compared to existing diagnostics?
U.S. Patent 8,623,410 covers both specific lipid species and analytical thresholds, making it relatively narrow compared to broad lipidomics methods. However, its focus on depression and the specific lipid biomarkers makes it meaningful for diagnostic test developers.
The patent does not claim therapeutic applications or compounds, limiting its scope to diagnostic methods. Its specificity to depression biomarkers distinguishes it from broader lipid biomarker patents targeting other diseases.
What analytical techniques underpin the patent’s claims?
The patent emphasizes mass spectrometry (MS), especially LC-MS/MS, as the core analytical technology for lipid quantification. The claims accommodate other techniques that can measure lipid levels, like NMR, though MS is the primary example.
Threshold analysis involves statistical or computational methods to interpret lipid level data, which can incorporate machine learning or other data-driven approaches.
How might future patent filings impact the landscape?
- New patents may target additional lipid species, lipid ratios, or combination panels to improve sensitivity and specificity.
- Integration of genetic markers with lipid profiling could extend patent claims.
- Method refinements around data analysis and interpretation methods provide avenues for further patent protection.
Key Takeaways
- U.S. Patent 8,623,410 protects lipid biomarker-based diagnostics for depression, emphasizing specific lipid species and threshold levels.
- Its claims are narrow to diagnostics, primarily analytical methods, with possible impact on competitors developing similar tests.
- The patent landscape is active, with several applications from academic and industry sources focusing on lipidomics for psychiatric diagnostics.
- Analytical techniques primarily involve mass spectrometry, with thresholds and statistical interpretation as key elements.
- Patent protection is likely to extend until around 2033, with ongoing research promising to broaden the scope.
FAQs
-
Can the patent's claims be challenged based on prior art?
The specificity to depression-related lipids and the analytical thresholds makes challenge feasible if prior lipidomics diagnostics exist with similar features before April 2012.
-
Does this patent cover therapeutic uses?
No, it strictly pertains to diagnostic methods based on lipid biomarker analysis.
-
What analytical methods are permissible under the patent claims?
Mass spectrometry (particularly LC-MS/MS) is emphasized, but other quantification techniques may be used if they meet the claim language.
-
Are there equivalents in other jurisdictions?
Similar claims appear in European and international applications, but patent scope varies with jurisdiction.
-
How does this patent influence drug development?
It does not directly impact drug discovery but guides diagnostic assay development, which could influence clinical trial designs and companion diagnostics.
References
- U.S. Patent 8,623,410.
- European Patent Application EP 2,771,654.
- Patent applications and publications from the University of Helsinki and industry partners.
More… ↓
⤷ Start Trial
|
